BRIEF: Shandong Gold’s profit doubles on high gold prices

1787.HK 600547.SHG

Gold producer Shandong Gold Mining Co. Ltd. (1787.HK; 600547.SH) on Wednesday reported revenue of 56.77 billion yuan ($7.9 billion) for the first half of 2025, up 24.01% year-on-year, while its net profit jumped 102.98% to 2.81 billion yuan.

The company attributed the strong growth mainly to high gold prices and an increase in self-produced gold sales, boosting both its revenue and profit. Its gold production reached 24.71 tons in the latest six-month period, compared with 24.52 tons a year earlier, while sales of self-produced gold stood at 23.60 tons. Net operating cash flow totaled 10.50 billion yuan, up 81.7%, mainly due to higher net inflows from trading activities.

Looking ahead, the company noted that global political and economic uncertainties remain high, with safe-haven demand expected to continue supporting gold prices.

Shandong Gold’s stock opened higher on Thursday in Hong Kong, closing at HK$29 by the midday break, up 1.19%.

By Lee Shih Ta

To subscribe to Bamboo Works weekly free newsletter, click here

,
, ,

Related Articles

RELATED ARTICLES

  1. Zijin Mining spinning off its overseas gold mining arm and taking it public, in order to benefit from surging gold price
    Zijin Mining sees gold in IPO for international arm
    2899.HK 601899.SHG
  2. High gold prices may take the shine off Hipine as it seeks Hong Kong IPO
  3. Chow Tai Fook rediscovers gold in convertible bonds
    1929.HK
  4. BRIEF: Shandong Gold profit surges in first half of 2025
    1787.HK 600547.SHG
  5. BRIEF: Shandong Gold logs strong first-quarter profit growth
    1787.HK
  6. YuHua Education’s profit doubles as it bids adieu to Thailand
    6169.HK
  7. BRIEF: Laopu Gold’s profit soars on growing brand influence
    6181.HK
Discover hidden China stock gems in our weekly newsletter

Follow us

Facebook Twitter Linkedin Weixin Weibo Youtube

Subscribe to Our Free eNewsletter

Subscribe

Check out our content with some of our syndication partners

factiva

Recent Articles

Kelun-Biotech reported rising sales of its signature cancer drug

Precision cancer drugs show promise for Kelun-Biotech

The company reported rising sales of its signature cancer drug and could get national insurance coverage for other key products, potentially boosting full-year earnings Key Takeaways: Topline revenue actually fell…
6990.HK
Illustration of China's hydrogen battery industry

China plays defense on EV batteries, offense on hydrogen

China rolls out new rules restricting the export of cutting-edge technology for EV battery manufacturing. How will this affect Chinese battery makers setting up factories abroad? And hydrogen fuel cell maker Refire reports its revenue fell 10% in the first half of the year. What does this say about a Chinese sector that's getting huge government support, but has yet to find a mass audience?
3750.HK 2570.HK